From: Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
Age (years) | Mild | Moderate | Severe | Source | |||
---|---|---|---|---|---|---|---|
(GMFCS level I/II) | (GMFCS level III) | (GMFCS level IV/V) | |||||
Mean | SE | Mean | SE | Mean | SE | ||
0-4 | 0.79 | 0.24 | 0.66 | 0.25 | 0.47 | 0.22 | -- |
5-12 | 0.72 | 0.26 | 0.54 | 0.27 | 0.24 | 0.22 | -- |
13-20 | 0.66 | 0.28 | 0.41 | 0.29 | 0.01 | 0.23 | 2,3 |
21-22 | 0.61 | 0.32 | 0.47 | 0.28 | -0.01 | 0.22 | -- |
23-32 | 0.57 | 0.35 | 0.53 | 0.27 | -0.04 | 0.21 | 3 |
> 32 | 0.57 | 0.35 | 0.53 | 0.27 | -0.04 | 0.21 | -- |